Clinical Trial

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 22, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.
Trial Details
NCT Number NCT05738980
Lead Sponsor Beijing Hospital
Conditions Hepatocellular Carcinoma
Enrollment 88 participants
Start Date 2023-02-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-22